Skip to main content
Log in

MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

MicroRNAs are small non-coding RNA molecules that have been shown to regulate the expression of genes linked to cancer. MicroRNA-148a (miR-148a) has recently been found to be involved in many critical processes in human malignancies. The present study is to clarify the expression pattern and prognostic role of miR-148b in human hepatocellular carcinoma (HCC). The expression of miR-148b was detected in 156 cases of HCC and 36 cases of normal control specimens by real-time PCR. Results showed that miR-148b expression was significantly decreased in HCC compared with that in normal control. It was also demonstrated that aberrant miR-148b expression was associated with vein invasion and TNM stage of HCC. Kaplan–Meier analysis showed that decreased miR-148b expression was associated with poor overall survival of patients. A multivariate survival analysis also indicated that miR-148b could be an independent prognostic marker. These results proved that miR-148b expression was decreased in HCC and associated with tumor invasion and progression. The present study also provides the first evidence that miR-148b could be an independent prognostic factor for patients with HCC, indicating the potential role of miR-148b as a prognostic marker in clinical practice, and the inhibition of miR-148b may even become a new therapeutic method for the treatment of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14(8):535–48. doi:10.1038/nrg3471.

    Article  CAS  PubMed  Google Scholar 

  2. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5. doi:10.1038/nature02871.

    Article  CAS  PubMed  Google Scholar 

  3. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;. doi:10.1038/bjc.2014.119.

    Google Scholar 

  4. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010;3(5):484–8. doi:10.1161/CIRCGENETICS.110.958363.

    Article  CAS  PubMed  Google Scholar 

  5. Jin XF, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33(5):601–13. doi:10.1007/s10571-013-9940-9.

    Article  CAS  PubMed  Google Scholar 

  6. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics: a comprehensive review. EMBO Mol Med. 2012;4(3):143–59. doi:10.1002/emmm.201100209.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130(9):2077–87. doi:10.1002/ijc.26232.

    Article  CAS  PubMed  Google Scholar 

  8. Xu Y, Li L, Xiang X, Wang H, Cai W, Xie J, et al. Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis. Gene. 2013;527(2):584–93. doi:10.1016/j.gene.2013.05.085.

    Article  CAS  PubMed  Google Scholar 

  9. Wang C, Ren R, Hu H, Tan C, Han M, Wang X et al (2014) MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chin J Cancer Res = Chung-kuo yen cheng yen chiu. 26(1):17–29. doi:10.3978/j.issn.1000-9604.2014.01.01.

  10. Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol. 2014;9(1):47. doi:10.1186/1746-1596-9-47.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Zou C, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y, et al. Up-regulated MicroRNA-181a induces carcinogenesis in Hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer. 2014;14(1):97. doi:10.1186/1471-2407-14-97.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 2014;9(2):e88393. doi:10.1371/journal.pone.0088393.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol. 2010;53(1):98–107. doi:10.1016/j.jhep.2010.02.021.

    Article  CAS  PubMed  Google Scholar 

  14. Salvi A, Sabelli C, Moncini S, Venturin M, Arici B, Riva P, et al. MicroRNA-23b mediates urokinase and c-met down modulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J. 2009;276(11):2966–82. doi:10.1111/j.1742-4658.2009.07014.x.

    Article  CAS  PubMed  Google Scholar 

  15. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140(1):322–31. doi:10.1053/j.gastro.2010.10.006.

    Article  CAS  PubMed  Google Scholar 

  16. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69(3):1135–42. doi:10.1158/0008-5472.CAN-08-2886.

    Article  CAS  PubMed  Google Scholar 

  17. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14(7):1170–9. doi:10.1007/s11605-010-1202-2.

    Article  PubMed  Google Scholar 

  18. Huang JJ, Yu J, Li JY, Liu YT, Zhong RQ. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol. 2012;29(4):2402–8. doi:10.1007/s12032-012-0210-3.

    Article  CAS  PubMed  Google Scholar 

  19. Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011;17(24):7574–83. doi:10.1158/1078-0432.CCR-11-1714.

    Article  CAS  PubMed  Google Scholar 

  20. Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One. 2012;7(4):e35331. doi:10.1371/journal.pone.0035331.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52(1):60–70. doi:10.1002/hep.23660.

    Article  CAS  PubMed  Google Scholar 

  22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  23. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    Article  PubMed  Google Scholar 

  24. Huang X, Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat. 2014;21(3):153–62. doi:10.1111/jvh.12222.

    Article  CAS  PubMed  Google Scholar 

  25. Chan DL, Alzahrani NA, Morris DL, Chua TC. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(1):31–41. doi:10.1111/jgh.12399.

    Article  PubMed  Google Scholar 

  26. Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8(9):e61361. doi:10.1371/journal.pone.0061361.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Ren W, Qi X, Jia J, Yang M, Han G. Prevalence of hepatocellular carcinoma in Chinese Budd-Chiari syndrome patients: an extended systematic review using Chinese-language databases. Eur J Gastroenterol Hepatol. 2013;25(10):1241–3. doi:10.1097/MEG.0b013e32836104a4.

    Article  PubMed  Google Scholar 

  28. Shen A, Zhang H, Tang C, Chen Y, Wang Y, Zhang C, et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013;28(5):793–800. doi:10.1111/jgh.12162.

    Article  PubMed  Google Scholar 

  29. Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, et al. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma: systematic review and meta-analysis. Cancer Med. 2013;2(6):862–71. doi:10.1002/cam4.150.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Yin Z, Fan X, Ye H, Yin D, Wang J. Short- and long-term outcomes after laparoscopic and open hepatectomy for hepatocellular carcinoma: a global systematic review and meta-analysis. Ann Surg Oncol. 2013;20(4):1203–15. doi:10.1245/s10434-012-2705-8.

    Article  PubMed  Google Scholar 

  31. Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Vigano R, Cordone G, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol. 2013;25(2):180–6. doi:10.1097/MEG.0b013e328359e550.

    Article  CAS  PubMed  Google Scholar 

  32. Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38(4):286–95. doi:10.1016/j.ejso.2012.01.006.

    Article  PubMed  Google Scholar 

  33. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325–39. doi:10.1245/s10434-012-2513-1.

    Article  PubMed  Google Scholar 

  34. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74. doi:10.1038/nrg3074.

    Article  CAS  PubMed  Google Scholar 

  35. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31. doi:10.1038/nrg1379.

    Article  CAS  PubMed  Google Scholar 

  36. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4(9):1179–84.

    Article  CAS  PubMed  Google Scholar 

  37. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849–64. doi:10.1038/nrc3166.

    Article  CAS  PubMed  Google Scholar 

  38. Zhao Y, Jia HL, Zhou HJ, Dong QZ, Fu LY, Yan ZW, et al. [Identification of metastasis-related microRNAs of hepatocellular carcinoma in hepatocellular carcinoma cell lines by quantitative real time PCR]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =. Chin J Hepatol. 2009;17(7):526–30.

    CAS  Google Scholar 

  39. Song Y, Xu Y, Wang Z, Chen Y, Yue Z, Gao P, et al. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int J Cancer. 2012;131(5):1042–51. doi:10.1002/ijc.26485.

    Article  CAS  PubMed  Google Scholar 

  40. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer. 2011;10:1. doi:10.1186/1476-4598-10-1.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zhiyong Zhang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Z., Zheng, W. & Hai, J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol 31, 984 (2014). https://doi.org/10.1007/s12032-014-0984-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0984-6

Keywords

Navigation